News Formal

This European biotech company could rally nearly 45%, says Morgan Stanley

  • 📰 CNBC
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Morgan Stanley is bullish on pelabresib, currently awaiting results from its Phase 3 MANIFEST-2 trial.

Recent data for cancer treatment manufacturer MorphoSys AG suggests the German biotech's shares could see a significant rally, according to Morgan Stanley. The bank upgraded MorphoSys American depositary shares to overweight from underweight on Friday, and raised its price target to $9.20 from $3.70, implying 45% upside from Thursday's close. "Despite increasing competition, our updated analysis suggests peak global sales of $1.

"In addition, while some clinical risk remains, the data so far suggests that MANIFEST-2 has a good chance of success, which should drive significant upside in the shares," Quigley said. To be sure, the analyst noted that "binary outcome and profit taking" have led to weak MorphoSys shares in recent weeks, but the risk-reward profile is positively skewed at current prices, he added.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 12. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

European stocks mixed; Chinese trade, European inflation data in focusEuropean stocks mixed; Chinese trade, European inflation data in focus
ソース: Investingcom - 🏆 450. / 53 続きを読む »